Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975891 · ClinicalTrials.gov registry record · Phase 4
Performance of Systane PRO Versus Refresh Optive Mega-3
A Phase 4 study of Dry Eye, sponsored by Scripps Poway Eyecare and Optometry.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06975891: Recruiting Phase 4 study of Dry Eye, sponsored by Scripps Poway Eyecare and Optometry.
NCT06975891 is a Phase 4 study of Dry Eye that is actively recruiting participants, run by Scripps Poway Eyecare and Optometry. The registered enrollment target is 35 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06975891, a Phase 4 study of Dry Eye, is actively recruiting participants, sponsored by Scripps Poway Eyecare and Optometry.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.
Primary Outcome
The OSDI© is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. The OSDI© is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function.
Conditions Studied
Interventions
- DRUG Systane PRO
- DRUG Refresh Optive MEGA-3
Study Locations (1)
California
- Scripps Poway Eyecare & Optometry - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 4 |
What NCT06975891 shows while recruiting
NCT06975891 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Systane PRO is the first listed.
NCT06975891 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06975891 about?
NCT06975891 is a clinical study titled "Performance of Systane PRO Versus Refresh Optive Mega-3". Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.
What is the current status of trial NCT06975891?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-05-15. Estimated completion is 2026-06-01.
What conditions does trial NCT06975891 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT06975891?
The interventions under investigation include: Systane PRO (DRUG), Refresh Optive MEGA-3 (DRUG).
Who is sponsoring clinical trial NCT06975891?
This trial is sponsored by Scripps Poway Eyecare and Optometry, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06975891 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06975891's enrollment target sits among peer trials
35 29th of 41 higher than 13 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI